MALT1 inhibitor MI-2 100 mg | 99.87%
TargetMol
MALT1 inhibitor MI-2
Search Results
MALT1 inhibitor MI-2 25 mg | 99.87%
TargetMol
MALT1 inhibitor MI-2
MALT1 inhibitor MI-2 5 mg | 99.87%
TargetMol
MALT1 inhibitor MI-2
MALT1 inhibitor MI-2 2 mg | 99.87%
TargetMol
MALT1 inhibitor MI-2
Elvitegravir 25 mg | 99.73%
TargetMol
Elvitegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.
More Information Supplier PageElvitegravir
Elvitegravir 5 mg | 99.73%
TargetMol
Elvitegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer.
More Information Supplier PageElvitegravir
QNZ46 25 mg | Purity Not Available
TargetMol
QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist.
More Information Supplier PageQNZ46
QNZ46 100 mg | Purity Not Available
TargetMol
QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist.
More Information Supplier PageQNZ46
Pilaralisib 2 mg | 98.24%
TargetMol
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
More Information Supplier PagePilaralisib
ID-8 200 mg | Purity Not Available
TargetMol
ID-8, a DYRK inhibitor, sustains embryonic stem cell self-renewal in long-term culture.
More Information Supplier PageID-8
